

HR 7828

PRICED Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: May 18, 2022

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (May 18, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7828>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (10 total)

| Cosponsor | Party / State | Role | Date Joined |
|---------------------------------------|---------------|------|--------------|
| Rep. DeLauro, Rosa L. [D-CT-3] | D · CT | | May 18, 2022 |
| Rep. Doggett, Lloyd [D-TX-35] | D · TX | | May 18, 2022 |
| Rep. Garcia, Jesus G. "Chuy" [D-IL-4] | D · IL | | May 18, 2022 |
| Rep. Kaptur, Marcy [D-OH-9] | D · OH | | May 18, 2022 |
| Rep. Khanna, Ro [D-CA-17] | D · CA | | May 18, 2022 |
| Rep. Pocan, Mark [D-WI-2] | D · WI | | May 18, 2022 |
| Rep. Westerman, Bruce [R-AR-4] | R · AR | | May 18, 2022 |
| Rep. Krishnamoorthi, Raja [D-IL-8] | D · IL | | May 24, 2022 |
| Rep. Jayapal, Pramila [D-WA-7] | D · WA | | Jul 12, 2022 |
| Rep. Levin, Andy [D-MI-9] | D · MI | | Jul 12, 2022 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------------------|---------|-------------|--------------|
| Energy and Commerce Committee | House | Referred To | May 18, 2022 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|-------------|--------------|--|
| 117 HR 8588 | Related bill | Nov 1, 2022: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. |
| 117 S 1898 | Related bill | May 27, 2021: Read twice and referred to the Committee on Finance. |

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Actions Timeline

- **May 18, 2022:** Introduced in House
- **May 18, 2022:** Referred to the House Committee on Energy and Commerce.